Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Care
Cancer detection company GRAIL has announced that Cleveland Clinic has joined GRAIL’s PATHFINDER Study, a prospective, multi-cancer clinical study that is evaluating the implementation of Galleri™, an investigational multi-cancer early detection blood test, into clinical practice for the first time. Today, most cancers are found too...


